Indevus Pharmaceuticals
Recent developments from Indevus Pharmaceuticals detailed
Published in Health Business Week, January 19th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Indevus Pharmaceuticals.
Report 1: Indevus Pharmaceuticals, Inc., (IDEV) announced the signing of the definitive supply agreement with Schering, AG, Germany for NEBIDO, a long-acting, injectable testosterone preparation for the treatment of male hypogonadism.
In July 2005, Indevus licensed the exclusive U.S. rights to NEBIDO from Schering, AG. NEBIDO, which was approved and launched in Europe last year, is the first injectable product for treating hypogonadism requiring...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2007-01-19)
More Articles from Health Business Week
- Adverse Drug Reaction
Bayer informs healthcare professionals of safety revisions to the Trasylol label - Alzheimer Disease
Dosing commenced in Phase IIa trial of PBT2 in early Alzheimer patients - Anemia
Roche submits added data to U.S. FDA to support license application for anti-anemia agent - Anthrax Vaccine
U.S. Health & Human Services cancels VaxGen's anthrax vaccine contract - Antibacterial Agents
New Drug Application submitted for investigational antibiotic Doripenem - Asthma
Half of newly diagnosed asthmatics do not fill prescriptions within a year of diagnosis - More from this issue of Health Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
